Barclays Maintains Overweight on 10x Genomics, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Luke Sergott maintains an Overweight rating on 10x Genomics (NASDAQ:TXG) but lowers the price target from $21 to $19.
November 01, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst Luke Sergott maintains an Overweight rating on 10x Genomics but lowers the price target from $21 to $19, indicating a slightly less optimistic outlook.
The Overweight rating suggests continued confidence in 10x Genomics, but the lowered price target indicates a tempered outlook. This mixed signal may result in neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100